188 Views
Z4. COVID-19 Treatment
Poster Session: COVID-19 Treatment
463 patients with mild to moderate symptoms of SARS-CoV2 received mAb: 355(176 Men) BAM, 108(53 Men) CAR/IMD. The median BMI was 31 (17.4 to 62.5), 85% Caucasian, 4% Asian, 3% African American, 4% Hispanic, 4% others. The average duration of symptoms was 3.4 days and included cough (74%), malaise (71%), Headache (28%), dyspnea (28%), rhinorrhea (25%), fever (20%), diarrhea (18%), and anosmia (14%). Risk factors included hypertension (65%), diabetes mellitus (32%), coronary artery disease (22%), asthma (16%), COPD (9%), CHF (9%), CKD (8%), active malignancy (6%), and immunocompromised state (7%). Those who received BAM were older (p=0.000) and have underlying dementia and congestive heart failure (p=0.025 and 0.034, respectively). 27 patients (2 CAR/IMG, 25 BAM) got admitted to the hospital due to worsening of their respiratory status and were treated for COVID-19. 4 patients in the BAM group and 0 in the CAR/IMD group died. 2 patients developed a mild allergic reaction to CAR/IMD, no other side effects were reported in both groups. 37 patients (19 CAR/IMD, 18 BAM) received mRNA COVID vaccine prior. Overall mortality rate was 0.8%. There was no significant difference between BAM and CAR/IMR in terms of hospitalization (p= 0.104) or mortality (p=0.268).
Conclusion: Treatment with BAM versus CAR/IMR was well tolerated and resulted in similar outcomes in terms of hospitalization or mortality.
Inderjit Mann, MD
Fellow
Renaissance School of Medicine at Stony Brook University
Stonybrook, New York, United States
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Melinda Monteforte, B.S/PharmD/BCPS AQ
Clinical pharmacist
Stony Brook University Hospital
Stony Brook, NY, United States
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Roderick Go, DO
Associate Professor of Clinical Medicine (Infectious Diseases)
Stony Brook University Hospital
Stony Brook, New York, United States
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.